166 related articles for article (PubMed ID: 17882952)
1. [Antitumor activities of various immunoconjugates composed of lidamycin and anti-type IV collagenase monoclonal antibody].
Feng Y; Zhen YS; Dai Y; Shang BY; Zhang M; He HW; Li BW; Shao RG
Yao Xue Xue Bao; 2007 Jul; 42(7):704-9. PubMed ID: 17882952
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of the antitumor activities of immunoconjugates composed of lidamycin and monoclonal antibody fab' fragment with different linkers].
Feng Y; Shao RG; Dai Y; Li BW; He HW; Ren KH
Yao Xue Xue Bao; 2010 May; 45(5):571-5. PubMed ID: 20931757
[TBL] [Abstract][Full Text] [Related]
3. [Antitumor effects of the immunoconjugate composed of lidamycin and monoclonal antibody 3G11].
Wang FQ; Shang BY; Zhen YS
Yao Xue Xue Bao; 2003 Jul; 38(7):515-9. PubMed ID: 14515796
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of anti-type IV collagenase monoclonal antibody and its lidamycin conjugate against colon carcinoma.
Li L; Huang YH; Li Y; Wang FQ; Shang BY; Zhen YS
World J Gastroenterol; 2005 Aug; 11(29):4478-83. PubMed ID: 16052675
[TBL] [Abstract][Full Text] [Related]
5. [Antitumor effect of lidamycin-containing monoclonal antibody immunoconjugate with downsized-molecule].
Liu XY; Zhen YS
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Dec; 23(6):563-7. PubMed ID: 12901099
[TBL] [Abstract][Full Text] [Related]
6. [Antitumor effect of the novel immunoconjugate composed of pingyangmycin and anti-type IV collagenase monoclonal antibody].
Dai Y; Liu XJ; Zhen YS
Yao Xue Xue Bao; 2006 Jan; 41(1):41-6. PubMed ID: 16683526
[TBL] [Abstract][Full Text] [Related]
7. [Immunoscintigraphy of anti-type IV collagenase monoclonal antibody in nude mice bearing human lung cancer xenograft].
Dai Y; Jia B; Wang F; Du J; Shang BY; Zhen YS
Ai Zheng; 2003 Dec; 22(12):1243-8. PubMed ID: 14693044
[TBL] [Abstract][Full Text] [Related]
8. [Inhibitory effects of the immunoconjugate composed of anti-type IV collagenase antibody Fab' fragment and lidamycin on tumor invasion and metastasis].
Feng Y; He HW; Li BW; Zhang ZX; Chen X; Li XF
Yao Xue Xue Bao; 2011 Dec; 46(12):1462-5. PubMed ID: 22375419
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of the molecule-downsized immunoconjugate composed of lidamycin and Fab' fragment of monoclonal antibody directed against type IV collagenase.
Fengqiang W; Boyang S; Yongsu Z
Sci China C Life Sci; 2004 Feb; 47(1):66-73. PubMed ID: 15382678
[TBL] [Abstract][Full Text] [Related]
10. [Antitumor effect of the immunoconjugate composed of antibiotic C1027 and Fab fragment from a monoclonal antibody directed against human hepatoma].
Li JZ; Jiang M; Xue YC; Zhen YS
Yao Xue Xue Bao; 1993; 28(4):260-5. PubMed ID: 8213168
[TBL] [Abstract][Full Text] [Related]
11. [Inhibitory effect of lidamycin on growth of colon carcinoma 26 and hepatic metastasis in mice].
Liu XJ; Dai Y; Shang Y; Li Y; Zhen YS
Ai Zheng; 2005 Jun; 24(6):641-5. PubMed ID: 15946470
[TBL] [Abstract][Full Text] [Related]
12. Efficient inhibition of B-cell lymphoma xenografts with a novel recombinant fusion protein: anti-CD20Fab-LDM.
Xin C; Ye S; Ming Y; Shenghua Z; Qingfang M; Hongxing G; Xu S; Yuanfu X; Yuan Z; Dongmei F; Juanni L; Yingdai G; Lianfang J; Rongguang S; Zhenping Z; Jianxiang W; Tao C; Chunzheng Y; Dongsheng X; Yongsu Z
Gene Ther; 2010 Oct; 17(10):1234-43. PubMed ID: 20463754
[TBL] [Abstract][Full Text] [Related]
13. Generation and antitumor effects of an engineered and energized fusion protein VL-LDP-AE composed of single-domain antibody and lidamycin.
Miao Q; Shang B; Ouyang Z; Liu X; Zhen Y
Sci China C Life Sci; 2007 Aug; 50(4):447-56. PubMed ID: 17653664
[TBL] [Abstract][Full Text] [Related]
14. Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin.
Fang H; Miao Q; Zhang S; Cheng X; Xiong D; Zhen Y
Sci China Life Sci; 2011 Mar; 54(3):255-62. PubMed ID: 21416325
[TBL] [Abstract][Full Text] [Related]
15. [Lidamycin induces apoptosis of human gastric carcinoma BGC823 cells and inhibits xenograft growth in nude mice].
Zhang SH; Chen J; Jiang M; Zhen YS
Yao Xue Xue Bao; 2008 Jun; 43(6):601-4. PubMed ID: 18822962
[TBL] [Abstract][Full Text] [Related]
16. An enediyne-energized single-domain antibody-containing fusion protein shows potent antitumor activity.
Miao QF; Liu XY; Shang BY; Ouyang ZG; Zhen YS
Anticancer Drugs; 2007 Feb; 18(2):127-37. PubMed ID: 17159599
[TBL] [Abstract][Full Text] [Related]
17. [Lidamycin inhibits the proliferation of HERG K+ channel highly expressing cancer cells and shows synergy with anticancer drugs].
Shang BY; Shang Y; Zhen YS; Chen SZ
Yao Xue Xue Bao; 2011 Nov; 46(11):1321-5. PubMed ID: 22260022
[TBL] [Abstract][Full Text] [Related]
18. [Bioluminescence imaging evaluation of the inhibitory effect of lidamycin on lung metastasis of human fibrosarcoma in athymic mice].
Zhang SH; Zhong GS; He HW; Cheng X; Zhen YS
Yao Xue Xue Bao; 2011 Jan; 46(1):45-9. PubMed ID: 21465808
[TBL] [Abstract][Full Text] [Related]
19. A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30
Wang R; Li L; Zhang S; Li Y; Wang X; Miao Q; Zhen Y
Mol Oncol; 2018 Mar; 12(3):339-355. PubMed ID: 29316337
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapy of experimental renal cell carcinoma with a novel conjugate of monoclonal antibody 138H11 and calicheamicin thetaI1.
Knoll K; Wrasidlo W; Scherberich JE; Gaedicke G; Fischer P
Cancer Res; 2000 Nov; 60(21):6089-94. PubMed ID: 11085532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
